The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Company profile
Ticker
BMY
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1096271 BC ULC • 345 Park LLC • 9643435 Canada Inc. • Abraxis BioScience Australia Pty Ltd. • Abraxis BioScience International Holding Company, Inc. • Abraxis BioScience Puerto Rico, LLC • Abraxis BioScience, Inc. • Abraxis BioScience, LLC • AbVitro LLC • Acetylon Pharmaceuticals, Inc. ...
IRS number
220790350
BMY stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
25 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
8-K
Departure of Directors or Certain Officers
18 Mar 24
PRE 14A
Preliminary proxy
18 Mar 24
8-K
Strengthening Neuroscience Portfolio
18 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
23 Feb 24
Transcripts
BMY
Earnings call transcript
2024 Q1
25 Apr 24
BMY
Earnings call transcript
2023 Q4
2 Feb 24
BMY
Earnings call transcript
2023 Q3
26 Oct 23
BMY
Earnings call transcript
2023 Q2
27 Jul 23
BMY
Earnings call transcript
2023 Q1
27 Apr 23
BMY
Earnings call transcript
2022 Q4
2 Feb 23
BMY
Earnings call transcript
2022 Q3
26 Oct 22
BMY
Earnings call transcript
2022 Q2
27 Jul 22
BMY
Earnings call transcript
2022 Q1
29 Apr 22
BMY
Earnings call transcript
2021 Q4
4 Feb 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.57 bn | 7.57 bn | 7.57 bn | 7.57 bn | 7.57 bn | 7.57 bn |
Cash burn (monthly) | 285.67 mm | 32.42 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.96 bn | 222.95 mm | n/a | n/a | n/a | n/a |
Cash remaining | 5.60 bn | 7.35 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 19.6 | 226.6 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
53.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1959 |
Opened positions | 190 |
Closed positions | 560 |
Increased positions | 540 |
Reduced positions | 1034 |
13F shares | Current |
---|---|
Total value | 52.73 tn |
Total shares | 1.09 bn |
Total puts | 7.41 mm |
Total calls | 11.59 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 198.16 mm | $10.17 tn |
JPM JPMorgan Chase & Co. | 90.05 mm | $4.62 tn |
STT State Street | 89.45 mm | $4.59 tn |
Capital International Investors | 61.53 mm | $3.16 tn |
FMR | 42.61 mm | $2.19 tn |
MS Morgan Stanley | 29.38 mm | $1.51 tn |
NTRS Northern Trust | 24.01 mm | $1.23 tn |
Primecap Management | 23.53 mm | $1.21 tn |
LGEN Legal & General | 19.81 mm | $1.02 tn |
BK Bank Of New York Mellon | 17.02 mm | $873.41 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Karin Shanahan | Common Stock, $0.10 par value | Payment of exercise | Dispose F | No | No | 52.99 | 1,196 | 63.38 k | 5,336 |
1 Apr 24 | Karin Shanahan | Common Stock, $0.10 par value | Option exercise | Acquire M | No | No | 0 | 3,306 | 0.00 | 6,532 |
1 Apr 24 | Karin Shanahan | RSU Common Stock, $0.10 par value | Option exercise | Dispose M | No | No | 0 | 3,306 | 0.00 | 6,613 |
31 Mar 24 | Yale Phyllis R | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 54.23 | 645.399 | 35.00 k | 27,595.249 |
31 Mar 24 | Storch Gerald L | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 54.23 | 691.499 | 37.50 k | 88,158.649 |
31 Mar 24 | Samuels Theodore R. II | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 54.23 | 921.999 | 50.00 k | 47,858.919 |
31 Mar 24 | Derica W Rice | Deferred Share Units Common Stock, $0.10 par value | Grant | Acquire A | No | No | 54.23 | 691.499 | 37.50 k | 23,634.109 |
News
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
25 Apr 24
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results
25 Apr 24
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
25 Apr 24
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
25 Apr 24
Bristol-Myers Squibb Q1 2024 Adj EPS $(4.40) Beats $(4.44) Estimate, Sales $11.865B Beat $11.458B Estimate
25 Apr 24
Press releases
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
25 Apr 24
PureTech Announces Annual Results for Year Ended December 31, 2023
25 Apr 24
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
17 Apr 24